user

Optimal dose for renoprotection by the angiotensin II receptor blocker candesartan in patients with type 2 diabetes and nephropathy.

被引：0
|
作者：
Rossing, K
Christensen, PK
Jacobsen, PK
Hansen, BV
Parving, HH
机构：
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[2] Univ Aarhus, Fac Hlth Sci, DK-8000 Aarhus C, Denmark
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：653A / 653A
页数：1
相关论文
共 50 条
  • [21] Angiotensin II type 1 receptor blocker, candesartan ameliorates cognitive impairment in type-2 diabetes mice with improvement of insulin resistance
    Tsukuda, Kana
    Mogi, Masaki
    Li, Jian-Mei
    Iwanami, Jun
    Min, Li-Juan
    Chen, Rui
    Iwai, Masaru
    Horiuchi, Masatsugu
    JOURNAL OF HYPERTENSION, 2006, 24 : 83 - 83
  • [22] CARDIOVASCULAR OUTCOME OF AN ANGIOTENSIN II RECEPTOR BLOCKER CANDESARTAN, IN JAPAN
    Suzuki, H.
    Araki, R.
    DRUGS OF TODAY, 2010, 46 (06) : 427 - 431
  • [23] Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy
    Schjoedt, K. J.
    Astrup, A.
    Persson, F.
    Tarnow, L.
    Rossing, P.
    Parving, H.-H.
    DIABETOLOGIA, 2007, 50 : S460 - S461
  • [24] Good news for patients with type 2 diabetes: angiotensin receptor blocker treatment delays progression of diabetic nephropathy
    Schiffrin, EL
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2002, 11 (02): : 173 - 175
  • [25] Impact of the angiotensin-receptor blocker candesartan in preventing diabetes in patients with heart failure
    Yusuf, S
    Ostergren, JB
    Gerstein, H
    Pfeffer, MA
    Swedberg, K
    Granger, CB
    McMurray, JJV
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 473A - 473A
  • [26] Candesartan:: A new-generation angiotensin II AT1 receptor blocker:: Pharmacology, antihypertensive efficacy, renal function, and renoprotection
    Morsing, P
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1999, 10 : S248 - S254
  • [27] Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    Walser, M
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09): : 706 - 706
  • [28] Effects of the angiotensin II type 1 receptor blocker candesartan on cardiovascular events in high-risk patients
    Kondo, J
    Sone, T
    Tsuboi, H
    Mukawa, H
    Kosokabe, T
    Uesugi, F
    Morishima, I
    EUROPEAN HEART JOURNAL, 2001, 22 : 716 - 716
  • [29] Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease
    Kondo, J
    Sone, T
    Tsuboi, H
    Mukawa, H
    Morishima, I
    Uesugi, M
    Kona, T
    Kosaka, T
    Yoshida, T
    Numaguchi, Y
    Matsui, H
    Murohara, T
    Okumura, K
    AMERICAN HEART JOURNAL, 2003, 146 (06)
  • [30] Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes
    Ritz, E
    Dikow, R
    ANNALS OF MEDICINE, 2002, 34 (7-8) : 507 - 513
12345